A hallmark of human glioblastomas is that oncogenic signalings stimulated by overexpressed genes such as EGFR and EGFRvIII are aberrantly active, rendering these tumors highly malignant, and inherently resistant to combination therapies, resulting in an extremely poor prognosis of patients with malignant gliomas. A major barrier of this clinical challenge is the lack of a complete understanding of the mechanisms underlying the aggressiveness of these tumors and ineffectiveness of therapies for gliomas. The goal of this project is to define the role of ESDN, endothelial and smooth muscle cell-derived neuropilin-like protein (other names, DCBLD2 and CLCP1) in tumorigenesis and therapy-resistance of malignant human glioblastomas. ESDN is expressed at high levels in vascular injury, metastatic lung cancer and breast cancer. Our preliminary studies show that the ESDN gene is amplified in ~50% of clinical glioma specimens and preferentially up-regulated in classical and mesenchymal subtypes of glioblastomas that overexpress EGFR and EGFRvIII. Knockdown of ESDN in tumor xenografts significantly suppressed EGFRvIII-promoted glioma growth and invasion in the brain of animals. Mechanistically, EGFRvIII and EGF induce tyrosine phosphorylation (p-Y) of Y621 and Y750 of ESDN that activate TRAF6-Akt- and CrkII-Rac1- signaling and promote glioblastoma cell survival and invasion. Based on these observations, in this project, we propose a research plan directed at elucidating mechanisms by which ESDN augments EGFRvIII-stimulated glioma tumorigenesis and exploring therapeutic application of targeting ESDN to inhibit EGFRvIII-expressing brain gliomas. We will first investigate how ESDN affects EGFRvIII-stimulated glioma growth and invasion through dissociation of TRAF6 and binding of CrkII to specific tyrosine residues of ESDN that are phosphorylated by EGF and EGFRvIII stimulation. We will then determine clinical significance of the induced p-Y of ESDN with activation of oncogenic EGFR/EGFRvIII signaling pathways in primary glioma tumor specimens (Aims 1 and 2). Using short-term cultured primary glioblastoma (GBM) xenograft and an induced de novel brain glioma models, we will explore pre-clinical approaches to assess the impact of inhibition of ESDN on the efficacies of chemotherapeutic agents, cisplatin and temozolomide on EGFR- and EGFRvIII-expressing glioblastomas in the brain of animals (Aim 3). Therefore, this proposal reveals an unrecognized signaling path by which EGFR and EGFRvIII stimulate TRAF6-Akt- and CrkII-signaling through ESDN, thereby promoting glioma growth and invasion. Elucidation of this novel mechanism holds promise to a better understanding of the oncogenic signaling-promoted glioma tumorigenesis and to overcome the insidious glioma resistance to current therapies. This project also addresses an urgent challenge in neuro-oncology and offers an enormous potential for developing novel therapies that could prove effective, thus eliminating the major barrier in treating patients with malignant glioblastomas.
Modulation of Oncogenic Signaling in Glioblastomas Human glioblastomas are characterized with malignant growth, rapid progression and intrinsic invasiveness, rendering these tumors virtually resistant to existing therapies, and the great propensity for tumor recurrence. In this application, we propose to investigate a novel mechanism by which oncogenic EGFRvIII and EGFR promote glioblastoma malignancy and resistant to therapies through activation of ESDN- TRAF6/CrkII signaling. The proposed work holds promise to elucidate the glioblastoma malignancy and to overcome the tumor resistance to combination therapies.
|Zhang, L; Zhang, W; Li, Y et al. (2016) SHP-2-upregulated ZEB1 is important for PDGFRÎ±-driven glioma epithelial-mesenchymal transition and invasion in mice and humans. Oncogene 35:5641-5652|
|Kim, Sung-Hak; Ezhilarasan, Ravesanker; Phillips, Emma et al. (2016) Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-ÎºB-dependent Manner. Cancer Cell 29:201-13|
|Eckerdt, Frank; Alvarez, Angel; Bell, Jonathan et al. (2016) A simple, low-cost staining method for rapid-throughput analysis of tumor spheroids. Biotechniques 60:43-6|
|Zhang, Haipeng; Lin, Yuan; Li, Kai et al. (2016) Naturally Existing Oncolytic Virus M1 Is Nonpathogenic for the Nonhuman Primates After Multiple Rounds of Repeated Intravenous Injections. Hum Gene Ther 27:700-11|
|Li, Yinghui; Zhou, Qi-Ling; Sun, Wenjie et al. (2015) Non-canonical NF-ÎºB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat Cell Biol 17:1327-38|
|Lu, Songjian; Lu, Kevin N; Cheng, Shi-Yuan et al. (2015) Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets. PLoS Comput Biol 11:e1004257|
|Chandran, Uma R; Luthra, Soumya; Santana-Santos, Lucas et al. (2015) Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells. Genom Data 5:333-336|
|Feng, Haizhong; Li, Yanxin; Yin, Yuhua et al. (2015) Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor Î±. Neuro Oncol 17:832-42|
|Feng, H; Hu, B; Vuori, K et al. (2014) EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene 33:2504-12|
|Ma, Hsin-I; Hueng, Dueng-Yuan; Shui, Hao-Ai et al. (2014) Intratumoral decorin gene delivery by AAV vector inhibits brain glioblastomas and prolongs survival of animals by inducing cell differentiation. Int J Mol Sci 15:4393-414|
Showing the most recent 10 out of 21 publications